Post-approval studies (Phase 4)Study completedNCT01333501What this trial is testingFingolimod Versus Interferon Beta 1b in Cognitive SymptomsWho this might be right forMultiple Sclerosis Novartis Pharmaceuticals 151
Testing effectiveness (Phase 2)Study completedNCT01742052What this trial is testingDose-finding Study of MT-1303Who this might be right forRelapsing-remitting Multiple Sclerosis Tanabe Pharma Corporation 415
Early research (Phase 1)Ended earlyNCT01318421What this trial is testingELND002 in Patients With Relapsing Forms of Multiple SclerosisWho this might be right forMultiple Sclerosis Elan Pharmaceuticals 12
Large-scale testing (Phase 3)Active Not RecruitingNCT04578639What this trial is testingOcrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS DiseaseWho this might be right forRelapsing Remitting Multiple Sclerosis Haukeland University Hospital 214
Not applicableUnknownNCT04116424What this trial is testingVIGIP-SEP2: Evaluation of the Impact of the Training of Patients by a Nurse on the Adverse Drug Reaction Reporting by RRMS Patient Via a Mobile Application: Randomized Real-life StudyWho this might be right forMultiple Sclerosis University Hospital, Caen 46
Not applicableNot Yet RecruitingNCT07292480What this trial is testingMonthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease ActivityWho this might be right forMultiple Sclerosis (MS) - Relapsing-remitting Centre Hospitalier Universitaire de Nīmes 84
Testing effectiveness (Phase 2)WithdrawnNCT00986960What this trial is testingEffect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)Who this might be right forMultiple Sclerosis University at Buffalo
Post-approval studies (Phase 4)Study completedNCT00871780What this trial is testingA Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) PatientsWho this might be right forRelapsing Remitting Multiple Sclerosis (RRMS) Biogen 224
Not applicableStudy completedNCT01233245What this trial is testingBetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus ProgramWho this might be right forRelapsing Remitting MS (RRMS)Secondary Progressive MS (SPMS) Bayer 1,077
Not applicableStudy completedNCT05684016What this trial is testingAssessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAMWho this might be right forMultiple Sclerosis, Relapsing-Remitting George Washington University 75
Large-scale testing (Phase 3)UnknownNCT01333358What this trial is testingEvaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis PatientsWho this might be right forMultiple Sclerosis Central Texas Neurology Consultants 30
Early research (Phase 1)Ended earlyNCT01808482What this trial is testingA First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)Who this might be right forMultiple Sclerosis, Relapsing-Remitting GlaxoSmithKline 16
Not applicableLooking for participantsNCT06267781What this trial is testingRRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line TherapiesWho this might be right forMultiple Sclerosis IRCCS San Raffaele 30
Large-scale testing (Phase 3)Ended earlyNCT03283397What this trial is testingA Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMSWho this might be right forMultiple Sclerosis, Relapsing-Remitting Bosnalijek D.D 301
Not applicableUnknownNCT04030819What this trial is testingEffectiveness of a Schema Therapy on Anxiety in Patients With Multiple SclerosisWho this might be right forAnxiety Paris Nanterre University 106
Testing effectiveness (Phase 2)UnknownNCT02587715What this trial is testingAllogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMSWho this might be right forMultiple Sclerosis, Relapsing-Remitting Novo Cellular Medicine Institute LLP 69
Not applicableStudy completedNCT01592097What this trial is testingExploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMSWho this might be right forMultiple Sclerosis University of Southern California 51
Post-approval studies (Phase 4)Study completedNCT02205489What this trial is testingManagement Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADAWho this might be right forRelapsing-remitting Multiple Sclerosis Genzyme, a Sanofi Company 58
Not applicableStudy completedNCT01075880What this trial is testingPost-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®Who this might be right forMultiple Sclerosis, Relapsing-Remitting Merck KGaA, Darmstadt, Germany 300
Large-scale testing (Phase 3)Study completedNCT02792218What this trial is testingEfficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple SclerosisWho this might be right forRelapsing Multiple Sclerosis Novartis Pharmaceuticals 930